AbbVie Inc (ABBV)vsTG Therapeutics Inc (TGTX)
ABBV
AbbVie Inc
$230.01
+0.06%
HEALTHCARE · Cap: $391.50B
TGTX
TG Therapeutics Inc
$53.94
-0.99%
HEALTHCARE · Cap: $7.58B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 8870% more annual revenue ($62.82B vs $700.35M). TGTX leads profitability with a 65.9% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.61. TGTX earns a higher WallStSmart Score of 70/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
TGTX
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$230.01
$83.79 premium
Intrinsic value data unavailable for TGTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Every $100 of equity generates 79 in profit
Keeps 66 of every $100 in revenue as profit
Revenue surging 69.6% year-over-year
Earnings expanding 300.0% YoY
Attractively priced relative to earnings
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 13.1x book value
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 65.9% and operating margin at 17.0%. Revenue growth of 69.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.68 — expect wider price swings.
TGTX is growing revenue faster at 69.6% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (70/100 vs 63/100), backed by strong 65.9% margins and 69.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?